Anemia at older age: etiologies, clinical implications, and management

Blood

Volumn 131, Issue 5, 2018, Pages 505-514

  Stauder, Reinhard ^a   Valent, Peter ^b   Theurl, Igor ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT;

AGED; ANEMIA; BLOOD TRANSFUSION; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; CLONAL ANEMIA; CYANOCOBALAMIN DEFICIENCY; EPIDEMIOLOGICAL DATA; FOLIC ACID DEFICIENCY; HUMAN; IRON DEFICIENCY; LABORATORY DIAGNOSIS; MEDICATION THERAPY MANAGEMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; UNEXPLAINED ANEMIA; AGING; BLOOD; LATE ONSET DISORDER; ONSET AGE; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; AGING; ANEMIA; HUMANS; LATE ONSET DISORDERS;

EID: 85041303346     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-07-746446     Document Type: Review

References (82)

1. Gaskell H, Derry S, Andrew Moore R, McQuay HJ. Prevalence of anaemia in older persons: systematic review. BMC Geriatr. 2008;8:1.
2. Merchant AA, Roy CN. Not so benign hae-matology: anaemia of the elderly. Br J Haematol. 2012;156(2):173-185.
3. Stauder R, Thein SL. Anemia in the elderly: clinical implications and new therapeutic concepts. Haematologica. 2014;99(7): 1127-1130.
4. Artz AS, Thirman MJ. Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. J Gerontol A Biol Sci Med Sci. 2011;66A(8):925-932.
5. Valent P. Anaemia of the elderly (AOE): does it exist and does it matter in clinical practice? Eur J Clin Invest. 2008;38(10):782-783.
6. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31(6): 727-736.
7. Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8(43):73483-73500.
8. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
9. Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol. 2014;89(1):88-96.
10. Blanc B, Finch CA, Hallberg L, et al. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405: 5-37.
11. Shavelle RM, MacKenzie R, Paculdo DR. Anemia and mortality in older persons: does the type of anemia affect survival? Int J Hematol. 2012;95(3):248-256.
12. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006; 107(5):1747-1750.
13. Steensma DP, Tefferi A. Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc. 2007; 82(8):958-966.
14. Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med. 2005;165(19):2214-2220.
15. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006;107(10):3841-3846.
16. Bach V, Schruckmayer G, Sam I, Kemmler G, Stauder R. Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging. 2014;9:1187-1196.
17. Tettamanti M, Lucca U, Gandini F, et al. Prevalence, incidence and types of mild anemia in the elderly: the “Health and Anemia” population-based study. Haematologica. 2010;95(11):1849-1856.
18. Denny SD, Kuchibhatla MN, Cohen HJ. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med. 2006;119(4):327-334.
19. Lucca U, Tettamanti M, Mosconi P, et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the “Health and Anemia” study. PLoS One. 2008;3(4):e1920.
20. Hong CH, Falvey C, Harris TB, et al. Anemia and risk of dementia in older adults: findings from the Health ABC study [published correction appears in Neurology. 2013;81(10): 939].
21. Neurology. 2013;81(6):528-533.
22. Chen-Edinboro LP, Murray-Kolb LE, Simonsick EM, et al. Association between non-iron-deficient anemia and insomnia symptoms in community-dwelling older adults: the Baltimore Longitudinal Study of Aging [published online ahead of print 20 January 2017]. J Gerontol A Biol Sci Med Sci. doi:10.1093/ gerona/glw332.
23. Onder G, Penninx BW, Cesari M, et al. Anemia is associated with depression in older adults: results from the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2005;60(9):1168-1172.
24. Penninx BW, Pahor M, Cesari M, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc. 2004;52(5): 719-724.
25. den Elzen WP, Willems JM, Westendorp RG, de Craen AJ, Assendelft WJ, Gussekloo J. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study. CMAJ. 2009; 181(3-4):151-157.
26. Beghé C, Wilson A, Ershler WB. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. Am J Med. 2004;116(7, suppl 1):3-10.
27. Balducci L. Anemia, fatigue and aging. Transfus Clin Biol. 2010;17(5-6):375-381.
28. Chaves PH, Semba RD, Leng SX, et al. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: the Women’s Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci. 2005;60(6): 729-735.
29. Chaves PH, Ashar B, Guralnik JM, Fried LP. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc. 2002;50(7):1257-1264.
30. Riva E, Tettamanti M, Mosconi P, et al. Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study. Haematologica. 2009;94(1):22-28.
31. Penninx BW, Pahor M, Woodman RC, Guralnik JM. Anemia in old age is associated with increased mortality and hospitalization. J Gerontol A Biol Sci Med Sci. 2006;61(5): 474-479.
32. Zakai NA, French B, Arnold AM, et al. Hemoglobin decline, function, and mortality in the elderly: the Cardiovascular Health Study. Am J Hematol. 2013;88(1):5-9.
33. Patel KV, Longo DL, Ershler WB, et al. Haemoglobin concentration and the risk of death in older adults: differences by race/ ethnicity in the NHANES III follow-up. Br J Haematol. 2009;145(4):514-523.
34. Ahmed T, Haboubi N. Assessment and management of nutrition in older people and its importance to health. Clin Interv Aging. 2010; 5:207-216.
35. Gordon SR, Smith RE, Power GC. The role of endoscopy in the evaluation of iron deficiency anemia in patients over the age of 50. Am J Gastroenterol. 1994;89(11):1963-1967.
36. Loikas S, Koskinen P, Irjala K, et al. Vitamin B12 deficiency in the aged: a population-based study. Age Ageing. 2007;36(2):177-183.
37. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood. 1991;78(10): 2564-2567.
38. Wang CQ, Udupa KB, Lipschitz DA. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol. 1995;162(1):134-138.
39. Gomes AC, Gomes MS. Hematopoietic niches, erythropoiesis and anemia of chronic infection. Exp Hematol. 2016;44(2):85-91.
40. Takeda A, Toda T, Shinohara S, Mogi Y, Matsui N. Factors contributing to higher he-matocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 2002;40(1):104-109.
41. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009; 113(21):5277-5286.
42. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10): 1011-1023.
43. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704): 2090-2093.
44. Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am. 2014;28(4): 671-681.
45. den Elzen WP, de Craen AJ, Wiegerinck ET, Westendorp RG, Swinkels DW, Gussekloo J. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica. 2013;98(3):448-454.
46. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007; 109(1):353-358.
47. Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. Science. 2009;325(5942):877-880.
48. Choi SO, Cho YS, Kim HL, Park JW. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem Biophys Res Commun. 2007;356(1):312-317.
49. Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab. 2010;95(10):4743-4747.
50. Hou Y, Zhang S, Wang L, et al. Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene. 2012;511(2): 398-403.
51. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000; 51:245-270.
52. Theurl I, Hilgendorf I, Nairz M, et al. On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver. Nat Med. 2016;22(8):945-951.
53. Lupescu A, Bissinger R, Goebel T, et al. Enhanced suicidal erythrocyte death contributing to anemia in the elderly. Cell Physiol Biochem. 2015;36(2):773-783.
54. Pretorius E, du Plooy JN, Bester J. A comprehensive review on eryptosis. Cell Physiol Biochem. 2016;39(5):1977-2000.
55. Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254.
56. Baylis D, Bartlett DB, Patel HP, Roberts HC. Understanding how we age: insights into inflammaging. Longev Healthspan. 2013;2:8.
57. Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50(7): 1268-1271.
58. Bloomer SA, Kregel KC, Brown KE. Heat stress stimulates hepcidin mRNA expression and C/EBPa protein expression in aged rodent liver. Arch Gerontol Geriatr. 2014;58(1):145-152.
59. Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflammaging. Ageing Res Rev. 2008;7(2):83-105.
60. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev. 2011;243(1):136-151.
61. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327): 842-847.
62. Artz AS, Xue QL, Wickrema A, et al. Unexplained anaemia in the elderly is characterised by features of low grade inflammation. Br J Haematol. 2014;167(2): 286-289.
63. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181.
64. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-2498.
65. Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007;31(11): 1461-1468.
66. Valent P, Bain BJ, Bennett JM, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012;36(1):1-5.
67. Valent P. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. Leuk Res. 2008;32(9):1333-1337.
68. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin 1 granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-1046.
69. Valent P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology Am Soc Hematol Educ Program. 2012;2012:485-491.
70. Valent P, Jäger E, Mitterbauer-Hohendanner G, et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res. 2011;1(4):531-541.
71. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3):1052-1057.
72. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52(1):217-222.
73. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997;30(6):912-922.
74. Tay HS, Soiza RL. Systematic review and meta-analysis: what is the evidence for oral iron supplementation in treating anaemia in elderly people? Drugs Aging. 2015;32(2): 149-158.
75. Gasche C, Ahmad T, Tulassay Z, et al; AEGIS Study Group. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21(3):579-588.
76. Tarantino G, Brilli E, Zambito Y, Giordano G, Equitani F. Sucrosomial Iron: a new highly bioavailable oral iron supplement [abstract]. Blood. 2015;126(23). Abstract 4561.
77. Silay K, Akinci S, Yalcin A, et al. The status of iron absorption in older patients with iron deficiency anemia. Eur Rev Med Pharmacol Sci. 2015;19(17):3142-3145.
78. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(suppl 1):S4-S9.
79. Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017; 26(4):266-275.
80. Agnihotri P, Telfer M, Butt Z, et al. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc. 2007;55(10): 1557-1565.
81. Ferrucci L, Guralnik JM, Bandinelli S, et al. Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol. 2007;136(6):849-855.
82. ABIM Foundation. Choosing Wisely: lists—American Society of Hematology. http://www.choosingwisely.org/clinician-lists/ american-society-hematology-red-blood-cell-transfusions-for-anemia/. Accessed 22 September 2017.